Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 172 citing articles:

Lecanemab in Early Alzheimer’s Disease
Christopher H. van Dyck, Chad J. Swanson, Paul Aisen, et al.
New England Journal of Medicine (2022) Vol. 388, Iss. 1, pp. 9-21
Open Access | Times Cited: 2752
Challenges and hopes for Alzheimer’s disease
Suren A. Tatulian
Drug Discovery Today (2022) Vol. 27, Iss. 4, pp. 1027-1043
Closed Access | Times Cited: 197
Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer’s Disease: A Focus on Aducanumab and Lecanemab
Mingchao Shi, Fengna Chu, Feiqi Zhu, et al.
Frontiers in Aging Neuroscience (2022) Vol. 14
Open Access | Times Cited: 192
iPSC-based disease modeling and drug discovery in cardinal neurodegenerative disorders
Hideyuki Okano, Satoru Morimoto
Cell stem cell (2022) Vol. 29, Iss. 2, pp. 189-208
Open Access | Times Cited: 120
Role of Aducanumab in the Treatment of Alzheimer’s Disease: Challenges and Opportunities
Miguel Vaz, Vítor Silva, Cristina Monteiro, et al.
Clinical Interventions in Aging (2022) Vol. Volume 17, pp. 797-810
Open Access | Times Cited: 120
Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications
Fernándo González‐Ortiz, Przemysław R. Kac, Wagner S. Brum, et al.
Molecular Neurodegeneration (2023) Vol. 18, Iss. 1
Open Access | Times Cited: 106
Aducanumab for the treatment of Alzheimer's disease: a systematic review
Afroza Rahman, Md. Anwar Hossen, Mirza Farhana Iqbal Chowdhury, et al.
Psychogeriatrics (2023) Vol. 23, Iss. 3, pp. 512-522
Open Access | Times Cited: 58
The FDA-approved anti-amyloid-β monoclonal antibodies for the treatment of Alzheimer’s disease: a systematic review and meta-analysis of randomized controlled trials
Wenxue Wu, Yi Ji, Zilan Wang, et al.
European journal of medical research (2023) Vol. 28, Iss. 1
Open Access | Times Cited: 54
The neuroprotective effects of targeting key factors of neuronal cell death in neurodegenerative diseases: The role of ER stress, oxidative stress, and neuroinflammation
Mohammad Sobhan Karvandi, Farzam Sheikhzadeh Hesari, Amir Reza Aref, et al.
Frontiers in Cellular Neuroscience (2023) Vol. 17
Open Access | Times Cited: 46
Clinically Important Benefits and Harms of Monoclonal Antibodies Targeting Amyloid for the Treatment of Alzheimer Disease: A Systematic Review and Meta-Analysis
Mark H. Ebell, Henry C Barry, Kanishka Baduni, et al.
The Annals of Family Medicine (2024) Vol. 22, Iss. 1, pp. 50-62
Open Access | Times Cited: 45
Efficacy and safety of anti-amyloid-β monoclonal antibodies in current Alzheimer's disease phase III clinical trials: A systematic review and interactive web app-based meta-analysis
Danko Jeremic, Juan D. Navarro‐López, Lydia Jiménez‐Díaz
Ageing Research Reviews (2023) Vol. 90, pp. 102012-102012
Closed Access | Times Cited: 41
Risk factors in developing amyloid related imaging abnormalities (ARIA) and clinical implications
Sarah J. Doran, Russell P. Sawyer
Frontiers in Neuroscience (2024) Vol. 18
Open Access | Times Cited: 25
Alzheimer’s disease and its treatment–yesterday, today, and tomorrow
A. Y. Kim, Salman Al Jerdi, Ryan B. MacDonald, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 18
Spontaneous ARIA-like Events in Cerebral Amyloid Angiopathy–Related Inflammation
Laura Antolini, Jacopo C. DiFrancesco, Marialuisa Zedde, et al.
Neurology (2021) Vol. 97, Iss. 18
Open Access | Times Cited: 98
Safety and Efficacy of Monoclonal Antibodies for Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Published and Unpublished Clinical Trials
Eleonora Lacorte, Antonio Ancidoni, Valerio Zaccaria, et al.
Journal of Alzheimer s Disease (2022) Vol. 87, Iss. 1, pp. 101-129
Open Access | Times Cited: 67
Brain Metabolic Alterations in Alzheimer’s Disease
Carlos G. Ardanaz, Marı́a J. Ramı́rez, Maite Solas
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 7, pp. 3785-3785
Open Access | Times Cited: 66
Spontaneous ARIA-like Events in Cerebral Amyloid Angiopathy–Related Inflammation: A Multicenter Prospective Longitudinal Cohort Study
Laura Antolini, Jacopo C. DiFrancesco, Marialuisa Zedde, et al.
(2021) Vol. 97, Iss. 18, pp. e1809-e1822
Open Access | Times Cited: 58
Aducanumab, a Novel Anti-Amyloid Monoclonal Antibody, for the Treatment of Alzheimer’s Disease: A Comprehensive Review
Hannah W. Haddad, Garett W. Malone, Nicholas J. Comardelle, et al.
Health psychology research (2022) Vol. 10, Iss. 1
Open Access | Times Cited: 49
Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: A randomised, double-blind, placebo-controlled phase 1a trial
Johannes Levin, Nand Sing, Sue Melbourne, et al.
EBioMedicine (2022) Vol. 80, pp. 104021-104021
Open Access | Times Cited: 49
Amyloid‐β PET in Alzheimer's disease: A systematic review and Bayesian meta‐analysis
Dan Ruan, Long Sun
Brain and Behavior (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 40
Lecanemab
James Burke, Kevin A. Kerber, Kenneth M. Langa, et al.
Neurology (2023) Vol. 101, Iss. 15, pp. 661-665
Open Access | Times Cited: 36
FDA approval of lecanemab: the real start of widespread amyloid PET use? — the EANM Neuroimaging Committee perspective
Antoine Verger, Igor Yakushev, Nathalie L. Albert, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2023) Vol. 50, Iss. 6, pp. 1553-1555
Open Access | Times Cited: 34
Sex and gender differences in Alzheimer’s disease, Parkinson’s disease, and Amyotrophic Lateral Sclerosis: A narrative review
Alessandra Nicoletti, Roberta Baschi, Calogero Edoardo Cicero, et al.
Mechanisms of Ageing and Development (2023) Vol. 212, pp. 111821-111821
Closed Access | Times Cited: 27
The role of microbiome-host interactions in the development of Alzheimer´s disease
Christian Weber, Alexander Dilthey, Patrick Finzer
Frontiers in Cellular and Infection Microbiology (2023) Vol. 13
Open Access | Times Cited: 25
Playing Russian Roulette with Alzheimer’s Disease Patients: Do the Cognitive Benefits of Lecanemab Outweigh the Risk of Edema, Stroke and Encephalitis?
Craig Atwood, George Perry
Journal of Alzheimer s Disease (2023) Vol. 92, Iss. 3, pp. 799-801
Closed Access | Times Cited: 23
Page 1 - Next Page

Scroll to top